Data Sheet (Cat.No.T14564)

TargetMol

BI-4924

Chemical Properties



CAS No. : 2244452-09-1

Formula: C21H20Cl2N2O6S

Molecular Weight: 499.36

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BI-4924 is a selective and potent inhibitor of phosphoglycerate dehydrogenase (PHGDH) (IC50=3 nM) that disrupts serine biosynthesis by intracellular trapping, and can be used in the study of diseases caused by dysfunction.
Targets(IC50)	Dehydrogenase
In vitro	BI-4924 is a potent NADH/NAD+-competitive PHGDH inhibitor, demonstrating high selectivity against most other dehydrogenase targets[1].

Solubility Information

Solubility	DMSO: 100 mg/mL (200.26 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.01 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0026 mL	10.0128 mL	20.0256 mL
5 mM	0.4005 mL	2.0026 mL	4.0051 mL
10 mM	0.2003 mL	1.0013 mL	2.0026 mL
50 mM	0.0401 mL	0.2003 mL	0.4005 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Weinstabl H, et al. Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis. J Med Chem. 2019 Jul 31.

Harald WEINSTABL， et,al.Tosylacetate based compounds and derivatives thereof as phgdh inhibitors: US20220008386A1.